Peregrine Pharmaceuticals, Inc. (Peregrine), incorporated in June 1981, is a biopharmaceutical company developing monoclonal antibodies for the treatment and diagnosis of cancer. The Company's pipeline of investigational monoclonal antibodies is based on two technology platforms, including PS-targeting antibodies and DNA/histone-targeting antibodies. Bavituximab is the Company's therapeutic PS-targeting antibody, which has demonstrated therapeutic potential and represents a new approach to treating cancer. PGN650 is the Company's PS-targeting imaging agent that represents a potential new approach to imaging cancer. The Company is conducting three randomized Phase II trials for bavituximab in combination with standard chemotherapy for front and second-line non-small cell lung cancer (NSCLC) and front-line pancreatic cancer. In addition to these company-sponsored trials for bavituximab, the Company has four investigator-sponsored trials (IST) looking at different treatment combinations and additional oncology indications.
2-year weekly chart
Address
14282 Franklin Avenue
TUSTIN, CA 92780
United States
Key stats and ratios
|
| Net profit margin | -69.81% | -276.50% |
| Operating margin | -73.32% | -276.18% |
| EBITD margin | - | -270.22% |
| Return on average assets | -53.50% | -133.65% |
| Return on average equity | -131.10% | -338.29% |
| Employees | 172 |
No comments:
Post a Comment